A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy

Trial Profile

A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Cediranib (Primary) ; Olaparib (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 Planned End Date changed from 30 Sep 2019 to 31 Oct 2019.
    • 29 Sep 2017 Planned primary completion date changed from 30 Sep 2019 to 31 Oct 2019.
    • 29 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top